Frederick Good

Herbert Smith Freehills (Hong Kong)
Lawyer

Frederick is a competition specialist with experience in both private practice and enforcement.Frederick is a specialist in EU, UK and Hong Kong competition law. In addition to his experience in private practice, Frederick has significant regulatory experience in Hong Kong. He was previously a case manager at the Hong Kong Competition Commission where he investigated a range of conduct including cartels and abuse of dominance cases. Frederick’s practice encompasses competition law investigations (including dawn raids), merger control, general competition advisory and compliance. Prior to relocating to Hong Kong Frederick worked at an international law firm based in London.

Linked authors

Herbert Smith Freehills (Hong Kong)
Herbert Smith Freehills (China)
Reed Smith (Hong Kong)
Herbert Smith Freehills (Hong Kong)

Articles

81 Bulletin

William Hallatt, Hannah Cassidy, Frederick Good, Adelaide Luke The Hong Kong Competition Authority and the Securities and Futures Commission sign a memorandum of understanding to enhance collaboration and the exchange of information on competition issues in the securities and futures industry

33

On 28 April 2020, the Hong Kong Competition Commission (HKCC) and the Securities and Futures Commission (SFC) announced that they had signed a memorandum of understanding (MoU) to enhance collaboration and exchange of information, particularly in respect of competition issues in the securities (...)

Frances Xu, Adelaide Luke, Frederick Good The Chinese State Administration for Market Regulation fines three pharmaceutical companies for abuse of dominance in the distribution of injectable drug and confirms that medical devices sectors continue to be an enforcement priority amid the COVID-19 outbreak (Kanghui / Puyunhui / Taiyangshen)

48

On 9 April 2020, China’s State Administration for Market Regulation (SAMR) fined 3 pharmaceutical companies for abuse of dominance in the distribution of injectable calcium gluconate Active Pharmaceutical Ingredient (API). The three companies were found to be in breach of the PRC’s Anti-Monopoly (...)

Send a message